News & Analysis as of

Labeling AbbVie

Goodwin

BREAKING NEWS: FDA Denies Citizen Petitions Regarding Biosimilar Labeling

Goodwin on

FDA denied citizen’s petitions from Abbvie, the UAW Retiree Medical Benefits Trust, and the Pharmaceutical Research and Manufacturers of America (“PhRMA”) and Biotechnology Industry Organization (“BIO”) trade associations...more

Goodwin

FDA Issues Interim Response to PhRMA/BIO Joint Citizen Petition on Biosimilar Labeling

Goodwin on

As we previously reported, late last year the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Industry Organization (BIO) trade associations jointly submitted a Citizen Petition asking the FDA...more

K&L Gates LLP

The Name Game: Institutional Investors Submit Citizen Petition Regarding Biosimilar Labeling

K&L Gates LLP on

On November 23, 2015, a group of fifteen institutional investors submitted a citizen petition to the FDA regarding biosimilar labeling (“Investors’ Citizen Petition”). The group includes investors from the public sector and...more

K&L Gates LLP

The Name Game: AbbVie’s Citizen Petition Regarding Biosimilar Labeling

K&L Gates LLP on

On June 2, 2015, AbbVie submitted a citizen petition to the FDA arguing against its interim labeling requirements for biosimilar products under the Biologics Price Competition and Innovation Act (“BPCIA”). As of now, the FDA...more

Patterson Belknap Webb & Tyler LLP

FDA Approach to Labeling Treats Biosimilars Like Generics

One of the FDA’s recent biosimilar guidance documents has drawn criticism for eliminating labeling information necessary for physicians to make prescribing decisions. The guidance document, titled, “Scientific Considerations...more

5 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide